# NOVEL PI3K INHIBITORS DEMONSTRATE MARKED CYTOTOXICITY IN MODELS OF T-CELL LYMPHOMA, CAUSED APOPTOSIS AND WERE SYNERGISTIC WITH THE NOVEL ANTI-CD20 MONOCLONAL ANTIBODY UBLITUXIMAB IN MODELS OF B-CELL LYMPHOMA

Changchun Deng<sup>1</sup>, Peter Sportelli<sup>2</sup>, Richard Rodriguez<sup>1</sup>, Hari Miskin<sup>2</sup>, Swaroop Vakkalanka<sup>3</sup>, Srikant Viswanadha<sup>4</sup> and Owen A. O'Connor<sup>1</sup>



<sup>1</sup>Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY; <sup>2</sup>TG Therapeutics, Inc., New York, NY; <sup>3</sup>Rhizen Pharmaceuticals SA, La Chaux de Fonds, Switzerland; <sup>4</sup>Incozen Therapeutics Pvt. Ltd., Hyderabad, India



#### BACKGROUND

Activation of PI3K has been shown to be required for the proliferation and survival of cancer cells. A selective PI3K-delta inhibitor, GS-1101/CAL-101, has produced promising results in the treatment of lymphoid malignancies. More recently, new chemical entities targeting PI3K have been developed, with pharmacologic and pharmacodynamic features distinct from CAL-101. TGR-1202 and TGR-5237 are two novel and structurally related PI3K inhibitors that possess marked selectivity of the PI3Kδ isoform over other PI3K isoforms and a panel of 442 kinases. Here we present data that confirmed the specificity of these PI3Kδ inhibitors using cell-based and Human Whole Blood assays, and demonstrated the activity of TGR-1202 and TGR-5237 in B- and T- cell lymphoma models.

While CAL-101 as a single agent has demonstrated promising clinical activity, we hypothesize that combining PI3Kδ inhibitors and immunotherapy will become a highly effective strategy for the treatment of B-cell lymphoma. To investigate the hypothesis, we studied the pharmacologic interaction of TGR-1202 with a novel anti-CD20 monoclonal antibody, ublituximab. Ublituximab is a next generation anti-CD20 antibody currently in clinical development, and is characterized by a specific glycosylation profile, with a low fucose content, that enhances its antibody-dependent cell-mediated cytotoxicity (ADCC) response against malignant B cells. Here we present data that demonstrated marked synergy between TGR-1202 and ublituximab.


#### RESULTS

Table 1. Enzyme and Cell based Selectivity Assays

|                 | IC <sub>50</sub> /EC <sub>50</sub><br>(nM) | Fold-Selectivity |       |       |
|-----------------|--|------------------|-------|-------|
|                 | ΡΙ3Κδ                                      | ΡΙ3Κα            | РІЗКβ | ΡΙ3Κγ |
| TGR-1202        |  |                  |       |       |
| Enzyme          | 22.23                                      | >10000           | >50   | >48   |
| Cell-based      | 24.27                                      | >10000           | >34   | >17   |
| <b>TGR-5237</b> |  |                  |       |       |
| Enzyme          | 13.83                                      | >1000            | >54   | >9    |
| Cell-based      | 31.52                                      | >1000            | >30   | >12   |


activity Enzyme was determined using an PI3K HTRF Assay Kit (Millipore, Billerica, MA) with modifications. Cell **based** specificity towards PI3Kδ was determined in an IgMcell proliferation assay. For selectivity against PI3K  $\alpha$ ,  $\beta$ , or  $\gamma$  isoforms, pAKT was measured in NIH-3T3 or macrophages upon induction with specific antigens.


#### Figure 1. TGR-5237 induced lymphoma cell death as a single agent



**Enzyme activity** was determined by flow cytometry using the Annex-V kit from Invitrogen. WSU-NHL cells were exposed to the indicated drugs for 48 hours.

Figure 2. TGR-1202 and ublituximab (UTX) synergistically induced apoptosis (sub G0) and G2/M arrest in B-lymphoma cells






Cell cycle analysis was performed by flow cytometry. Cells were treated with either 1  $\mu$ M TGR-1202, 10 ng/ml UTX or a combination (10 ng/ml UTX + 1  $\mu$ M TGR-1202 ) and incubated for 72 h.


#### RESULTS

Figure 3. Ublituximab markedly enhanced caspase-3 activation induced by TGR-1202 in lymphoma cells




Activation of caspase 3 was measured using the Green FLICA assay kit in B-cell lymphoma cell lines treated with either 1 μM TRG-1202, 100 μg/ml UTX, or combination for 24 h. Note that TGR-1202 alone did not activate caspase-3 in the test cells were gated from CD45+ cells and estimated by Flow condition.

### Figure 4. TGR-1202 and ublituximab synergistically inhibited proliferation of B cells from human whole blood



LPS induced proliferation of CD19+ or CD20+ cells was determined by flow cytometry. Human Whole Blood was incubated with test agents prior to induction with LPS. 72 h later, CD19+ or CD20+ Cytometry.

Figure 5. Select T-lymphoma cell line was hypersensitive to TGR-5237



Cytotoxicity of B- and T-cell lymphoma cells was determined using the Cell Titer-Glo assay. Cells were exposed to TGR-5237 at indicated concentrations for 6 days. Survival of treated cells was expressed as a percentage of the untreated control cells. Note the concentration to achieve 50% inhibition for the cutaneous Tcell lymphoma line H9 was less than 80nM.

## CONCLUSIONS

- TGR-1202 and TGR-5237 are potent and selective inhibitors of PI3Kδ, and have single agent activity against B-lymphoma cell lines, and may be highly potent against select T-lymphoma cell lines.
- Combination of TGR-1202 and the novel anti-CD20 antibody, ublituximab, is highly effective in the induction of G2/M arrest and apoptosis in B-lymphoma cell lines.
- Combining selective PI3Kδ inhibitors and anti-CD20 immunotherapy may represent a promising strategy to treat B-cell lymphoma. Clinical studies evaluating the combination of TGR-1202 and ublituximab are warranted.

